CL2016002142A1 - Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas - Google Patents

Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas

Info

Publication number
CL2016002142A1
CL2016002142A1 CL2016002142A CL2016002142A CL2016002142A1 CL 2016002142 A1 CL2016002142 A1 CL 2016002142A1 CL 2016002142 A CL2016002142 A CL 2016002142A CL 2016002142 A CL2016002142 A CL 2016002142A CL 2016002142 A1 CL2016002142 A1 CL 2016002142A1
Authority
CL
Chile
Prior art keywords
tatk
compositions
formulations
fusion proteins
cdkl5 fusion
Prior art date
Application number
CL2016002142A
Other languages
English (en)
Inventor
Elisabetta Ciani
Franco Laccone
Original Assignee
Alma Mater Studiorum-Universita Di Bologna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alma Mater Studiorum-Universita Di Bologna filed Critical Alma Mater Studiorum-Universita Di Bologna
Publication of CL2016002142A1 publication Critical patent/CL2016002142A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737—C-reactive protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>EN LA PRESENTE SE DESCRIBEN COMPOSICIONES Y FORMULACIONES QUE CONTIENEN UNA PROTEÍNA DE FUSIÓN TATk-CDKL5. TAMBIÉN SE DESCRIBEN MÉTODOS PARA PRODUCIR UNA PROTEÍNA DE FUSIÓN TATk-CDKL5 A PARTIR DE VECTORES QUE CONTIENEN ADNc de TATk-CDKL5 Y MÉTODOS PARA TRANSDUCIR CÉLULAS CON LOS VECTORES QUE CONTIENEN ADNc DE TATk-CDKL5 Y LA PROTEÍNA DE FUSIÓN TATk-CDKL5.</p>
CL2016002142A 2014-02-28 2016-08-24 Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas CL2016002142A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28

Publications (1)

Publication Number Publication Date
CL2016002142A1 true CL2016002142A1 (es) 2017-09-08

Family

ID=53539745

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002142A CL2016002142A1 (es) 2014-02-28 2016-08-24 Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas

Country Status (33)

Country Link
US (4) US9290746B2 (es)
EP (2) EP3110837B1 (es)
JP (2) JP6629747B2 (es)
KR (1) KR102307276B1 (es)
CN (1) CN106255706A (es)
AU (2) AU2015221860B2 (es)
BR (1) BR112016019868B1 (es)
CA (1) CA2940401C (es)
CL (1) CL2016002142A1 (es)
CR (1) CR20160392A (es)
CY (2) CY1122644T1 (es)
DK (2) DK3608334T3 (es)
DO (1) DOP2016000220A (es)
EA (2) EA202190727A3 (es)
ES (2) ES2745335T3 (es)
HR (2) HRP20191511T1 (es)
HU (2) HUE055282T2 (es)
IL (2) IL247481B (es)
LT (2) LT3608334T (es)
MX (2) MX392778B (es)
MY (1) MY181566A (es)
NI (1) NI201600127A (es)
PE (1) PE20161406A1 (es)
PH (1) PH12016501689B1 (es)
PL (2) PL3608334T3 (es)
PT (2) PT3608334T (es)
RS (2) RS62244B1 (es)
SG (2) SG10202000537RA (es)
SI (2) SI3110837T1 (es)
SM (2) SMT202100478T1 (es)
SV (1) SV2016005264A (es)
WO (1) WO2015128746A2 (es)
ZA (2) ZA201606655B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3110837T1 (sl) * 2014-02-28 2019-12-31 Alma Mater Studiorum - Universita Di Bologna Fuzijski proteini TATK-CDKL5, sestavki, formulacije in njihova uporaba
BR112018077225A2 (pt) * 2016-06-28 2019-04-09 Alma Mater Studiorum - Università di Bologna proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas
KR20200090889A (ko) * 2017-11-30 2020-07-29 아미쿠스 세라퓨틱스, 인코포레이티드 Cdkl5 발현 변이체 및 cdkl5 융합 단백질
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
CA3156506A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
MX2023006445A (es) 2020-12-01 2023-08-10 Univ Pennsylvania Composiciones y usos de estas para el tratamiento del síndrome de angelman.
JP2024531296A (ja) * 2021-08-18 2024-08-29 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 組換えａａｖ製剤
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815582A1 (en) * 2010-10-25 2012-05-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Treatment of mecp2-associated disorders
SI3110837T1 (sl) * 2014-02-28 2019-12-31 Alma Mater Studiorum - Universita Di Bologna Fuzijski proteini TATK-CDKL5, sestavki, formulacije in njihova uporaba

Also Published As

Publication number Publication date
DK3608334T3 (da) 2021-08-23
IL275435A (en) 2020-08-31
EP3608334B1 (en) 2021-05-19
US20160194617A1 (en) 2016-07-07
WO2015128746A3 (en) 2015-11-26
MX2020001223A (es) 2022-05-31
NI201600127A (es) 2017-03-13
AU2019219743B2 (en) 2020-10-29
EA202190727A3 (ru) 2021-11-30
CA2940401C (en) 2022-11-29
JP2020062022A (ja) 2020-04-23
PT3110837T (pt) 2019-09-12
ES2885245T3 (es) 2021-12-13
EA038000B1 (ru) 2021-06-22
SV2016005264A (es) 2017-02-15
EP3608334A1 (en) 2020-02-12
ZA201906304B (en) 2022-03-30
BR112016019868B1 (pt) 2023-11-28
PL3608334T3 (pl) 2021-11-22
MX2016011167A (es) 2017-04-06
US20150247134A1 (en) 2015-09-03
EA201691691A1 (ru) 2017-05-31
PH12016501689A1 (en) 2016-10-03
SG10202000537RA (en) 2020-03-30
SMT201900504T1 (it) 2019-11-13
RS62244B1 (sr) 2021-09-30
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
US20200199549A1 (en) 2020-06-25
HRP20211324T1 (hr) 2021-11-26
MX392778B (es) 2025-03-24
AU2019219743A1 (en) 2019-09-19
HRP20191511T1 (hr) 2019-11-29
US9290746B2 (en) 2016-03-22
CA2940401A1 (en) 2015-09-03
US9944910B2 (en) 2018-04-17
AU2015221860B2 (en) 2019-09-12
PL3110837T3 (pl) 2020-04-30
PT3608334T (pt) 2021-08-25
WO2015128746A2 (en) 2015-09-03
BR112016019868A2 (pt) 2017-10-17
KR102307276B1 (ko) 2021-09-30
US10907138B2 (en) 2021-02-02
EA202190727A2 (ru) 2021-07-30
US10584318B2 (en) 2020-03-10
SI3110837T1 (sl) 2019-12-31
AU2015221860A1 (en) 2016-09-08
HUE045393T2 (hu) 2019-12-30
ZA201606655B (en) 2020-05-27
JP2017507655A (ja) 2017-03-23
JP6629747B2 (ja) 2020-01-15
NZ723371A (en) 2023-11-24
CY1122644T1 (el) 2021-03-12
IL275435B (en) 2021-07-29
SMT202100478T1 (it) 2021-09-14
DK3110837T3 (da) 2019-09-16
PE20161406A1 (es) 2017-01-14
IL247481B (en) 2020-07-30
CY1124727T1 (el) 2022-07-22
US20180327725A1 (en) 2018-11-15
KR20170002372A (ko) 2017-01-06
CR20160392A (es) 2017-06-12
SG11201606863YA (en) 2016-09-29
CN106255706A (zh) 2016-12-21
IL247481A0 (en) 2016-11-30
JP6896050B2 (ja) 2021-06-30
EP3110837B1 (en) 2019-06-12
ES2745335T3 (es) 2020-02-28
HUE055282T2 (hu) 2021-11-29
RS59344B1 (sr) 2019-10-31
PH12016501689B1 (en) 2016-10-03
SI3608334T1 (sl) 2021-11-30
LT3110837T (lt) 2019-10-10
DOP2016000220A (es) 2016-12-15
EP3110837A2 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
SV2016005264A (es) Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas
CO2019000395A2 (es) Genes de mini–distrofina optimizados y casetes de expresión y su uso
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CL2019000259A1 (es) Anticuerpos, antimiostatina, polipéptidos que contienen regiones fc variantes y métodos de uso.(divisional solicitud 201701584)
CL2017001736A1 (es) Anticuerpos anti-cd47 y uso de los mismos.
AR107078A1 (es) Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
CL2017003023A1 (es) Anticuerpos anti-ctla-4 y métodos de uso de los mismos.
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
MX369149B (es) Construcciones de anticuerpos para cdh19 y cd3.
BR112019012343A2 (pt) anticorpos il-11ra
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
EA201501028A1 (ru) Конструкции митохондриальных белков и их применение
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
MX2018003445A (es) Expresion de proteinas que contienen fc.
MX2020002552A (es) Métodos y composiciones para preparar proteína surfactante d (sp-d).
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
EA201791437A1 (ru) Композиции микросфер c инкапсулированным в липиде газом и соответствующие способы
MX2020002551A (es) Metodos, composiciones y celulas para preparar proteina surfactante d (sp-d).
AR110871A1 (es) Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas
AR103294A1 (es) Composiciones y procedimientos para la glicosilación de proteínas